DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c20e82/hungary_pharmaceut) has announced the addition of the "Hungary Pharmaceuticals and Healthcare Report Q4 2011" report to their offering.
The Hungary Pharmaceuticals and Healthcare Report provides industry professionals and strategists, corporate analysts, pharmaceutical associations, government departments and regulatory bodies with independent forecasts and competitive intelligence on Hungary's pharmaceuticals and healthcare industry.
The report continues to project that the Szll Klmn structural reforms plan, which aims to achieve savings of HUF120bn (US$580mn) over three years from Hungary's medicine budget will lead to year on- year (y-o-y) contractions in 2012 and 2013. However, the research stresses that the 30% contraction in public reimbursement funding will not lead to an equivalent contraction of drug market expenditure.
BMI notes that the method the government will employ to achieve these savings have yet to be revealed, creating considerable complexity in the forecast scenario, although the report expects fresh details to be prepared by the authorities by the end of September 2011.
Headline Expenditure Projections:
- Pharmaceuticals: HUF678bn (US$3.27bn) in 2010 to HUF690bn (US$3.76bn) in 2011; +1.8% in local currency terms and +14.7% in US dollar terms. Forecast broadly unchanged in local currency terms, up significantly in US dollar terms from Q311.
- Healthcare: HUF1,942bn (US$9.38bn) in 2010 to HUF1,993bn (US$10..85bn) in 2011; +2.6% in local currency terms and +15.7% in US dollar terms. Historic data revised, forecast broadly unchanged in local currency terms, up significantly in US dollar terms from Q311.
- Medical devices: HUF112.23bn (US$542mn) in 2010 to HUF115.67bn (US$630mn) in 2011; +3.1% in local currency terms and +16.2% in US dollar terms. Forecast up moderately due to analyst modification.
Companies Mentioned:
- Egis Pharmaceuticals (Servier)
- Eli Lilly
- Gedeon Richter
- GlaxoSmithKline
- Merck & Co
- Novartis
- Pfizer
- Sanofi-Aventis
- Teva
For more information visit http://www.researchandmarkets.com/research/c20e82/hungary_pharmaceut